Your browser doesn't support javascript.
loading
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath, Dennis; Temperton, Nigel; Mayora-Neto, Martin; Da Costa, Kelly; Cantoni, Diego; Horlacher, Reinhold; Günther, Armin; Brosig, Alexander; Morath, Jenny; Jakobs, Barbara; Groettrup, Marcus; Hoschuetzky, Heinz; Rohayem, Jacques; Ter Meulen, Jan.
Afiliação
  • Horvath D; Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
  • Temperton N; Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany.
  • Mayora-Neto M; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Da Costa K; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Cantoni D; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Horlacher R; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Günther A; trenzyme GmbH, Konstanz, Germany.
  • Brosig A; trenzyme GmbH, Konstanz, Germany.
  • Morath J; trenzyme GmbH, Konstanz, Germany.
  • Jakobs B; trenzyme GmbH, Konstanz, Germany.
  • Groettrup M; trenzyme GmbH, Konstanz, Germany.
  • Hoschuetzky H; Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
  • Rohayem J; nanoTools Antikoerpertechnik GmbH & Co. KG, Teningen, Germany.
  • Ter Meulen J; Riboxx Pharmaceuticals, Radebeul, Dresden, Germany and Institute of Virology, Dresden University of Technology, Dresden, Germany.
Sci Rep ; 13(1): 4648, 2023 03 21.
Article em En | MEDLINE | ID: mdl-36944687

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Influenza Humana / Vacinas contra COVID-19 / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Influenza Humana / Vacinas contra COVID-19 / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article